Navigation Links
Selexis SA to Present and Partner at the BIO-Europe Spring

Geneva, Switzerland (PRWEB) March 08, 2013

Geneva, Switzerland (PRWEB) March 8, 2013 – Selexis SA announced today the Company’s vice president of business development, Armelle Gaussin, Ph.D., will present, “Proprietary and Unique Expression System for Versatile and Ubiquitous Transgene Expression” as part of the Cell Therapy/Regenerative Medicine Track on Tuesday, March 12, 2013 at 3:30 PM at the BIO-Europe Spring 2013 Partnering Conference being held March 11 – 13, 2013 at the Centre Covencions Internacional Barcelona (CCIB), in Barcelona, Spain. The Company will be also taking part in the pre-scheduled partnering meetings.

Presentation Abstract:
Selexis has developed a full expression platform based on proprietary epigenetic regulator elements, the Selexis Genetic Elements, enabling versatile and ubiquitous transgene expression in mammalian cells. This expression system has a wide range of application areas. In the cell therapy field, high and stable transgene expression is obtained in adult stem cells and also sustained upon cell differentiation both in vitro and in vivo. The platform also provides a simple, fast and reliable approach towards stable cell line development for the production of therapeutic proteins and offers a dedicated approach for difficult to express proteins.

Companies or individuals attending BIO-Europe Spring can schedule meetings with Selexis (registration required) by visiting:

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins.

Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Merck scientist Daria Hazuda presents Bernard Fields Lecture at 20th Conference on Retroviruses and Opportunistic Infections (CROI)
3. Brad Paisley Partners with LiveBeyond for the "Beat This Summer Tour Presented by Cracker Barrel"
4. Celiac Disease Foundation to Present the Nation's Largest National Education Conference and Gluten-Free EXPO
5. United Representatives Invited to Sierra Leone
6. Greater representation of elderly patients in Phase III trials are needed
7. Independent panel to present findings on diagnosing gestational diabetes mellitus
8. Dr. Steve Carstensen Presents First Webinar for Dental Division of American Sleep and Breathing Academy
9. Einstein researchers present on imaging advances
10. Additional noteworthy research to be presented at the 2013 Genitourinary Cancers Symposium
11. S.T.A.R. Clinic Presents Becoming a Galactic Citizen
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology: